Feiyu Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Feiyu Chen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chenling Meng
The University of Texas MD Anderson Cancer Center 1 Department of Experimental Radiation Oncology Houston, Texas
1 shared publication - Di Zhao
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Hongqi Teng
The University of Texas MD Anderson Cancer Center 1 Department of Experimental Radiation Oncology Houston, Texas
1 shared publication - Javier Leo
The University of Texas MD Anderson Cancer Center 1 Department of Experimental Radiation Oncology Houston, Texas
1 shared publication - Jie Zhang
The University of Texas MD Anderson Cancer Center 1 Department of Experimental Radiation Oncology Houston, Texas
1 shared publication - Justin J. Kim
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
1 shared publication
Latest Publications
- 9 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF25
Dual Functions of B7-H3–MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-Derived Suppressor Cells and Fibroblasts
B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3–targeting therapy. In this study, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a noncanonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs (M-MDSC) and induces cellular senescence. The senescent M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs (Gr-MDSC). Genetic deletion or pharmacologic inhibition of B7-H3/CD276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3–targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable antitumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms. Significance: Our studies uncovered a long-unknown B7-H3 signaling that orchestrates the cross-talk of cancer cells with myeloid and stromal cells in the host and provided novel mechanistic insights and effective combinatorial strategies for B7-H3–targeting immunotherapy in advanced prostate cancer among other malignancies.
- 9 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF25
Dual Functions of B7-H3–MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-Derived Suppressor Cells and Fibroblasts
B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3–targeting therapy. In this study, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSC) and cancer-associated fibroblasts (CAF), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a noncanonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs (M-MDSC) and induces cellular senescence. The senescent M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs (Gr-MDSC). Genetic deletion or pharmacologic inhibition of B7-H3/CD276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3–targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable antitumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms. Significance: Our studies uncovered a long-unknown B7-H3 signaling that orchestrates the cross-talk of cancer cells with myeloid and stromal cells in the host and provided novel mechanistic insights and effective combinatorial strategies for B7-H3–targeting immunotherapy in advanced prostate cancer among other malignancies.